Targets › NKG2C
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2030.
Immune activating receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib HLA-E loaded with signal sequence-derived peptides from non-classical MHC class Ib HLA-G molecules, likely playing a role in the generation and effector functions of adaptive natural killer (NK) cells and in maternal-fetal…. (UniProt, P26717)
Open in Phaseline: the race on NKG2C, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Masonic Cancer Center, University of Minnesota | AdaptNK Allogeneic KIR-HLA mismatched NK cell infusion enriched for CMV-induced adaptive NK cells | NCAM1, NKG2C | Phase 1 | Relapsed Adult AML | Mar 2030 |
Relapsed Adult AML (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.